Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: NVO stock price vs AMGN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at AMGN's multiple
Needs Annual EPS, AMGN P/E.
Implied fair value · at NVO's multiple
Needs Annual EPS, NVO P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Higher is better
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
NOVO NORDISK A S · implied price per share
Reporting currency could not be verified.
AMGEN INC · implied price per share
Reporting currency could not be verified.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
NVO · not enough data.
AMGN · not enough data.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
NVO vs PFE
Merck & Co., Inc.
NVO vs MRK
JOHNSON & JOHNSON
NVO vs JNJ
BRISTOL MYERS SQUIBB CO
NVO vs BMY
AbbVie Inc.
NVO vs ABBV
REGENERON PHARMACEUTICALS, INC.
NVO vs REGN
BIOGEN INC.
NVO vs BIIB
VERTEX PHARMACEUTICALS INC / MA
NVO vs VRTX
Gilead Sciences, Inc.
NVO vs GILD
Moderna, Inc.
NVO vs MRNA
Eli Lilly and Company
NVO vs LLY
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe NVO’s weak quality score and higher leverage are temporary and that its earnings multiple should rerate closer to AMGN levels, then the stock looks attractive on valuation because the current price is far below both AMGN-implied and DCF ranges.
NVO’s current price of $43.89 sits at the very bottom of its historical band of $39.50 to $48.28, while AMGN-implied value is far higher at $241.02 to $575.36 and the DCF range is $169.83 to $229.77. The market is therefore pricing NVO at a large discount on the provided valuation framework, but the gap is partially tempered by the fact that only P/E, P/S, EV/EBITDA, and EV/Revenue are available for comparison.
Supporting Metrics
